Prognostic value of peripheral blood mononuclear cell-associated HIV-1 DNA for virological outcome in asymptomatic HIV-1 chronic infection

Carmen Rodríguez-Sáinz a,∗, Ricardo Ramos b, Lara Valor a, Francisco López c, Beatriz Santamaría a, Diana C. Hernández a, Joana S.P. Cruz b, Joaquín Navarro a, Jara Modrego a, Diana Alecsandru a, Eduardo Fernández-Cruz a

a Clinical Immunology Division, Hospital General Universitario Gregorio Marañón, Microbiology Department, Universidad Complutense de Madrid, Madrid, Spain
b Laboratorio de Cuantificación Génica, Parque Científico de Madrid, Madrid, Spain
c Department Statistics, NUFARM21, Madrid, Spain

Article history:
Received 17 September 2009
Received in revised form 18 March 2010
Accepted 22 March 2010

Keywords:
PBMC HIV-1 DNA
Prognostic marker
Therapeutic vaccination
HIV-1 reservoir
HIV-1 RNA viremia
Asymptomatic HIV-1 chronic infection

ABSTRACT

Background: Studies in primary HIV-1 infection and advanced HIV-1 disease have demonstrated that HIV-1 DNA associated with peripheral blood mononuclear cells (PBMC HIV-1 DNA) has predictive value for disease progression.

Objectives: To analyse in asymptomatic HIV-1 chronic infection the predictive value of PBMC HIV-1 DNA for virological failure.

Study design: In 115 individuals who had previously participated in study STIR-2102, we retrospectively analysed the PBMC HIV-1 DNA by quantitative real-time PCR. Antiretroviral naïve patients (baseline pre-ART) received 6 weeks of ART prior to randomisation (baseline post-ART). The predictive value of PBMC HIV-1 DNA, HIV-1 RNA in plasma and CD4+ T cells, at baselines pre-ART and post-ART, was determined by Kaplan–Meier and Proportional Hazards Regression analyses.

Results: At baseline post-ART, 82% of patients showed suppression of HIV-1 RNA, however they maintained significant amounts of HIV-1 DNA (geometric mean: 690 copies/10⁶ PBMC). Pre-ART and post-ART levels of HIV-1 DNA and pre-ART levels of HIV-1 RNA showed predictive value (Log-Rank test: p < 0.001, p < 0.001, p = 0.003, respectively). In a multivariate model post-ART PBMC HIV-1 DNA was the stronger predictive variable (adjusted HR, 2.51 [95% CI, 1.33–4.73, p = 0.004]) independently of HIV-1 RNA (HR 1.74 [95% CI, 1.16–2.61, p = 0.007]).

Conclusions: PBMC HIV-1 DNA is an effective prognostic marker for virological outcome in individuals with asymptomatic HIV-1 chronic infection.

© 2010 Elsevier B.V. All rights reserved.

1. Background

Integration of HIV-1 DNA into host cell genomic DNA ensures viral persistence as a latent reservoir despite prolonged antiretroviral therapy (ART).1–9 The persistence of HIV-1 DNA in the cellular reservoir is one of the current challenges with regard to the control of the progression of HIV-1 infection.10–13 CD4+ T cell counts (CD4) and plasma HIV-1 RNA levels are the surrogate standards for HIV-1 disease progression.14–20 However, cell-associated HIV-1 DNA is a marker associated with the viral reservoir and with the spread of the virus.

Studies in patients with primary HIV-1 infection and with advanced HIV-1 chronic infection, either naïve or experienced for ART, have shown that early levels of HIV-1 DNA in PBMC and in CD4+ T cells have predictive value for long-term virologic outcome and for disease progression.21–33 However, there is scarce information on the prognostic value of PBMC-associated HIV-1 DNA for predicting the virological outcome of asymptomatic patients with HIV-1 chronic infection who starts ART.

2. Objectives

To evaluate in 115 antiretroviral naïve patients with asymptomatic HIV-1 chronic infection, who had previously participated in STIR-2102 trial,34,35 whether or not the levels of PBMC-associated HIV-1 DNA could have prognostic value beyond the current surrogate standards for the long-term virologic outcome.

Abbreviations: ART, antiretroviral therapy; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction; CD4, CD4+ T cell counts.

∗ Corresponding author at: Servicio de Inmunología Clínica, Laboratorio de Inmunogenética Molecular Clínica, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, C/Dr. Esquerdo 46, Madrid 28007, Spain. Tel.: +34 91 5868423; fax: +34 91 5866698.
E-mail address: crodriguez.hugm@salud.madrid.org (C. Rodríguez-Sáinz).

1386-6532/ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.jcv.2010.03.020